吉西他滨、奥沙利铂联合口服氟尿嘧啶类药物在胰腺癌一线化疗中的临床观察

发布时间：2018-11-17 08:28

【摘要】：目的:观察吉西他滨、奥沙利铂联合口服氟尿嘧啶类药物在胰腺癌一线治疗中的疗效与安全性。方法:自2011年1月至2017年1月,31例局部晚期或转移性胰腺癌患者于中国医学科学院肿瘤医院接受吉西他滨、奥沙利铂联合口服氟尿嘧啶类药物治疗,排除2例未评价疗效的患者,2例失访患者,共27例患者纳入研究。分别按照实体瘤的疗效评价标准(RECIST)1.0和国立癌症研究所毒性判定标准(NCI-CTC)4.0评价疗效和毒性。具体给药方案为:吉西他滨1OOOmg/m~2,化疗第一天静脉滴注;奥沙利铂85mg/m~2,化疗第一天静脉滴注;口服氟尿嘧啶类药物:卡培他滨1000mg/m~2,每日两次,连续口服八天或替吉奥40mg/m~2,每日两次,连续口服八天,每14天为1周期,每4周期评估疗效。结果:接受吉西他滨、奥沙利铂、口服氟尿嘧啶(卡培他滨或替吉奥)联合化疗方案的患者中位无进展生存时间(mPFS)及中位生存期(mOS)分别为:5.91个月(95%CI:2.24～9.59个月)、11.8个月(95%CI:10.8～12.8个月);客观缓解率(0RR)为:22.2%;疾病控制率(DCR)为:55.5%。3/4级不良事件包括中性粒细胞减少7例(25.9%)、腹泻1例(3.7%)、呕吐1例(3.7%)、口腔溃疡1例(3.7%)。结论:吉西他滨、奥沙利铂联合口服氟尿嘧啶类药物对局部晚期和转移性胰腺癌一线治疗中具有较好的疗效及安全性。
[Abstract]:Aim: to observe the efficacy and safety of gemcitabine and oxaliplatin combined with oral fluorouracil in the treatment of pancreatic cancer. Methods: from January 2011 to January 2017, 31 patients with locally advanced or metastatic pancreatic cancer were treated with gemcitabine, oxaliplatin and oral fluorouracil at the Cancer Hospital of the Chinese Academy of Medical Sciences. Two patients without evaluation and two patients without visit were excluded. 27 patients were included in the study. The efficacy and toxicity were evaluated according to (RECIST) 1.0 and NCI-CTC 4.0, respectively. The specific regimens were as follows: gemcitabine 1OOOmg / mc-2, intravenous drip on the first day of chemotherapy, oxaliplatin 85 mg / mm2, intravenous drip on the first day of chemotherapy; Oral fluorouracil drugs: capecitabine 1000mg / mm2, twice a day, or Tegueo 40mg / mt2, twice a day, for eight consecutive days, once every 14 days, every four cycles. Results: gemcitabine, oxaliplatin, The median progression-free survival time (mPFS) and median survival time (mOS) were 5.91 months (95 CI: 2.24 ~ 9.59 months) in patients with oral fluorouracil (capecitabine or tegiro). 11.8 months (95%CI:10.8~12.8 months); Objective remission rate (0RR) was 22. 2%; The disease control rate (DCR) was 55.5 / 3 / 4 adverse events including neutropenia in 7 cases (25.9%), diarrhea in 1 case (3.7%), vomiting in 1 case (3.7%) and oral ulcer in 1 case (3.7%). Conclusion: gemcitabine and oxaliplatin combined with oral fluorouracil are effective and safe in the treatment of advanced and metastatic pancreatic cancer.
【学位授予单位】：北京协和医学院
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R735.9

【参考文献】